Gabrielli Roberto, Rosati Maria S, Vitale Silvio, Siani Andrea, Caselli Giovanni
Department of Vascular and Endovascular Surgery, "Policlinico Casilino", Rome, Italy -
J Cardiovasc Surg (Torino). 2016 Aug;57(4):510-3.
The purpose of our study was to determine the efficacy of percutaneous thrombin treatment for iatrogenic femoral artery pseudoaneurysms (FAP) and to identify those criteria that may help to predict increased treatment failure risk and complications.
A number of 32 iatrogenic femoral pseudoaneurysms were treated with US-guided thrombin injection (group A), while four elderly patient with complex femoral pseudoaneurysm underwent compression assisted by removable "guidewire" (group B). Twenty-five were classified as simple (single lobe) and 11 as complex (at least two lobes with a single neck to the native vessel). Pseudoaneurysm volume, classification, thrombin dose, anticoagulation therapy status, and sheath size were considered independent prognostic factors.
All the 36 patients (pts) had initial complete femoral pseudoaneurysms thrombosis. The aneurysm was thrombosed on a Doppler ultrasound (US) follow-up in all the cases but four (group A), those who required the additional thrombin injection. A fatal complication occurred in one patient with complex FAP (group A).
Preliminary data suggest that US-guided percutaneous thrombin injection is a safe and effective method to treat iatrogenic pseudoaneurysms. Simple iatrogenic femoral pseudoaneurysms benefit a single injection of up to 500 units of topical thrombin. We recommend more caution in complex pseudoaneurysms treatment; it is preferable to perform thrombin injection first into the lobe which is not directly joined to the femoral artery. A longer bed rest and closer observation are mandatory during the subsequent 24 hours. If the lobe communicating with the femoral artery is still patent, it can be retreated. Alternatively, we propose a new strategy approach through compression assisted removable "guidewire".
我们研究的目的是确定经皮凝血酶治疗医源性股动脉假性动脉瘤(FAP)的疗效,并确定那些可能有助于预测治疗失败风险增加和并发症的标准。
32例医源性股动脉假性动脉瘤采用超声引导下凝血酶注射治疗(A组),4例老年复杂股动脉假性动脉瘤患者采用可移除“导丝”辅助压迫治疗(B组)。25例为简单型(单叶),11例为复杂型(至少两个叶且与天然血管有单一颈部)。假性动脉瘤体积、分类、凝血酶剂量、抗凝治疗状态和鞘管尺寸被视为独立的预后因素。
36例患者(pts)最初均实现股动脉假性动脉瘤完全血栓形成。除4例(A组)需要额外注射凝血酶的患者外,所有病例在多普勒超声(US)随访中动脉瘤均形成血栓。1例复杂FAP患者(A组)发生致命并发症。
初步数据表明,超声引导下经皮凝血酶注射是治疗医源性假性动脉瘤的一种安全有效的方法。简单的医源性股动脉假性动脉瘤单次注射高达500单位的局部凝血酶即可获益。我们建议在复杂假性动脉瘤治疗中更加谨慎;最好先将凝血酶注射到不直接与股动脉相连的叶中。在随后的24小时内必须延长卧床休息时间并密切观察。如果与股动脉相通的叶仍未闭塞,可以再次治疗。或者,我们提出一种通过可移除“导丝”辅助压迫的新策略方法。